Please ensure Javascript is enabled for purposes of website accessibility

Why Intuitive Surgical Stock Jumped 17% in April

By Jeremy Bowman - May 5, 2021 at 11:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A strong earnings report lifted the healthcare stock last month.

What happened

Shares of Intuitive Surgical (ISRG -1.91%) were climbing last month as the maker of the da Vinci surgical robot posted better-than-expected results in its first-quarter earnings report, easily beating estimates on the top and bottom lines. The stock also got a boost from an analyst upgrade earlier in the month as well as general optimism about the economic reopening and President Joe Biden's infrastructure bill, which includes money for healthcare.

According to data from S&P Global Market Intelligence, the stock finished last month up 17%. As you can see from the chart below, the stock gained through much of April before shooting higher on April 21 when its earnings report came out.

ISRG Chart

ISRG data by YCharts.

So what

Intuitive Surgical kicked off the month with a positive analyst note from Citigroup, which initiated coverage with a buy rating, saying that the company was expanding its robotic surgery platform into new areas like urology, gynecology, and general surgery, increasing its market opportunity.   

A group of health care workers

Image source: Getty Images.

The stock gained alongside the S&P 500 through the first half of the month, then shot up 10% when its earnings report came out.

Da Vinci procedures increased 16% in the period, and its installed base grew by 8%. That drove an 18% increase in revenue to $1.29 billion, which easily beat estimates at $1.11 billion. It was the fastest growth rate from the company, showing patients are becoming more comfortable with surgical procedures now that the COVID-19 threat is easing. Intuitive Surgical also posted strong growth on the bottom line as adjusted earnings per share increased from $2.70 to $3.52, easily outpacing estimates at $2.63.

Now what

As the company laps a weak performance last year due to the pandemic, it expects procedures to grow 22% to 26% this year with operating expenses rising 18% to 22%, indicating margins should expand.

Intuitive Surgical has a strong competitive position with unique technology and a razor-and-blades model that keeps customers locked in and delivers high margins. The healthcare stock is pricey but the business consistently delivers high growth. As it expands to new platforms, that steady growth should continue.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Intuitive Surgical. The Motley Fool recommends the following options: long January 2022 $580.0 calls on Intuitive Surgical and short January 2022 $600.0 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$233.71 (-1.91%) $-4.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.